{"title": "Reconstituci\u00f3n de la inmunidad espec\u00edfica del VIH contra el VIH", "author": "Linghua LI", "url": "https://ichgcp.net/es/clinical-trials-registry/NCT02563509", "hostname": "ichgcp.net", "description": "Objetivo de la investigaci\u00f3n: reconstituir el sistema de inmunidad espec\u00edfico anti-VIH de los pacientes con SIDA, de modo que los virus no puedan replicarse mas.... Registro de ensayos cl\u00ednicos. ICH GCP.", "sitename": "ichgcp.net", "date": "2015-09-13", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Reconstituci\u00f3n de la inmunidad espec\u00edfica del VIH contra el VIH\n5 de junio de 2019 actualizado por: Linghua LI,\n[Guangzhou 8th People's Hospital](https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Guangzhou%208th%20People%27s%20Hospital)\nObjetivo de la investigaci\u00f3n: reconstituir el sistema de inmunidad espec\u00edfico anti-VIH de los pacientes con SIDA, de modo que los virus no puedan replicarse masivamente cuando se interrumpa la HAART, y luego hacer posible la cura funcional del VIH.\nDescripci\u00f3n general del estudio\nEstado\nTerminado\nCondiciones\nIntervenci\u00f3n / Tratamiento\nDescripci\u00f3n detallada\nLa investigaci\u00f3n tiene como objetivo establecer nuevas estrategias de tratamiento del VIH. Mejorar\u00e1 significativamente los efectos de la terapia cl\u00ednica y reducir\u00e1 de manera efectiva la morbilidad y la mortalidad al reconstituir el sistema inmunitario de los pacientes infectados por el VIH y combinar m\u00faltiples estrategias de terapia. Por lo tanto, la investigaci\u00f3n podr\u00eda desarrollar un sistema de amplificaci\u00f3n de clonaci\u00f3n de inmunocitos in vitro y mejorar el sistema inmunol\u00f3gico antiviral gravemente da\u00f1ado antes mediante la transfusi\u00f3n de c\u00e9lulas clonadas modificadas por ant\u00edgeno espec\u00edfico del VIH. As\u00ed, los pacientes infectados por el VIH podr\u00edan suspender el medicamento antiviral tradicional, pero no desarrollar infecciones oportunistas, lo que obviamente podr\u00eda aumentar la calidad de vida de estos pacientes.\nTipo de estudio\nIntervencionista\nInscripci\u00f3n (Actual)\n30\nFase\n- Fase 1\nContactos y Ubicaciones\nEsta secci\u00f3n proporciona los datos de contacto de quienes realizan el estudio e informaci\u00f3n sobre d\u00f3nde se lleva a cabo este estudio.\nUbicaciones de estudio\n-\nPorcelana\n-\nGuangdong\n-\nGuangzhou, Guangdong, Porcelana, 510060\n- Guangzhou 8th People's Hospital\n-\n-\nCriterios de participaci\u00f3n\nLos investigadores buscan personas que se ajusten a una determinada descripci\u00f3n, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.\nCriterio de elegibilidad\nEdades elegibles para estudiar\n16 a\u00f1os a 60 a\u00f1os (Ni\u00f1o, Adulto)\nAcepta Voluntarios Saludables\nNo\nG\u00e9neros elegibles para el estudio\nTodos\nDescripci\u00f3n\nCriterios de inclusi\u00f3n:\n- infecci\u00f3n por VIH confirmada\n- Recibir HAART m\u00e1s de 6 meses\n- Carga viral del VIH < 50 copias/ml\n- Sin da\u00f1os graves de h\u00edgado y ri\u00f1\u00f3n.\n- El sujeto se ofreci\u00f3 voluntariamente a la investigaci\u00f3n y firm\u00f3 el consentimiento informado.\nCriterio de exclusi\u00f3n:\n- Con infecciones oportunistas graves\n- Con enfermedades cr\u00f3nicas graves como la diabetes, la enfermedad mental, et al.\n- Antecedentes de padecer pancreatitis durante TARGA.\n- Embarazada y amamantada.\n- Con mala adherencia\nPlan de estudios\nEsta secci\u00f3n proporciona detalles del plan de estudio, incluido c\u00f3mo est\u00e1 dise\u00f1ado el estudio y qu\u00e9 mide el estudio.\n\u00bfC\u00f3mo est\u00e1 dise\u00f1ado el estudio?\nDetalles de dise\u00f1o\n- Prop\u00f3sito principal: Tratamiento\n- Asignaci\u00f3n: Aleatorizado\n- Modelo Intervencionista: Asignaci\u00f3n paralela\n- Enmascaramiento: Ninguno (etiqueta abierta)\nArmas e Intervenciones\n|\n|\nGrupo de participantes/brazo\n|\n|\nIntervenci\u00f3n / Tratamiento\n|\n|\nExperimental: C\u00e9lulas CD8 espec\u00edficas del VIH\nTransfusi\u00f3n de c\u00e9lulas CD8 espec\u00edficas del VIH de 50 a 100 ml una vez a la semana durante cuatro veces.\n|\n|\nBasado en HAART, recibe transfusi\u00f3n de c\u00e9lulas CD8 espec\u00edficas del VIH.\n|\n|\nSin intervenci\u00f3n: Terapia regular\nSolo recibe terapia antirretroviral de gran actividad (TARGA).\n\u00bfQu\u00e9 mide el estudio?\nMedidas de resultado primarias\n|\n|\nMedida de resultado\n|\n|\nMedida Descripci\u00f3n\n|\n|\nPeriodo de tiempo\n|\n|\nEl n\u00famero y la funci\u00f3n de las c\u00e9lulas CD8 espec\u00edficas del VIH en pacientes con VIH\nPeriodo de tiempo: 6 meses\n|\n|\nEl cambio de diferenciaci\u00f3n, proliferaci\u00f3n, apoptosis, fenotipo, etc.\n|\n|\n6 meses\nMedidas de resultado secundarias\n|\n|\nMedida de resultado\n|\n|\nMedida Descripci\u00f3n\n|\n|\nPeriodo de tiempo\n|\n|\nTodos los eventos adversos\nPeriodo de tiempo: 6 meses\n|\n|\nEscalofr\u00edos, Fiebre, Dolor de cabeza, N\u00e1useas, V\u00f3mitos, Tos, Erupciones cut\u00e1neas, Choque anafil\u00e1ctico, Etal.\n|\n|\n6 meses\nColaboradores e Investigadores\nAqu\u00ed es donde encontrar\u00e1 personas y organizaciones involucradas en este estudio.\nPatrocinador\nColaboradores\nInvestigadores\n- Investigador principal: Hui Zhang, doctor, Sun Yat-sen University\nPublicaciones y enlaces \u00fatiles\nLa persona responsable de ingresar informaci\u00f3n sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.\nPublicaciones Generales\n-\n[Fidler S, Olson A, Fox J, Phillips A, Morrison C, Thornhill J, Bucher H, Muga R, Porter K. The importance of viral blips and duration of therapy initiated in primary infection in maintaining viral control after stopping cART. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19820. doi: 10.7448/IAS.17.4.19820. eCollection 2014.](https://ichgcp.net/es/clinical-trials-registry/publications/20378-the-importance-of-viral-blips-and-duration-of-therapy-initiated-in-primary-infection-in-maintaining)\n-\n[Archin NM, Sung JM, Garrido C, Soriano-Sarabia N, Margolis DM. Eradicating HIV-1 infection: seeking to clear a persistent pathogen. Nat Rev Microbiol. 2014 Nov;12(11):750-64. doi: 10.1038/nrmicro3352.](https://ichgcp.net/es/clinical-trials-registry/publications/20379-eradicating-hiv-1-infection-seeking-to-clear-a-persistent-pathogen)\n-\n[Chew N, Tan E, Li L, Lim R. HIV-1 tat and rev upregulates osteoclast bone resorption. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19724. doi: 10.7448/IAS.17.4.19724. eCollection 2014.](https://ichgcp.net/es/clinical-trials-registry/publications/20380-hiv-1-tat-and-rev-upregulates-osteoclast-bone-resorption)\n-\n[Abdel-Mohsen M, Deng X, Danesh A, Liegler T, Jacobs ES, Rauch A, Ledergerber B, Norris PJ, Gunthard HF, Wong JK, Pillai SK. Role of microRNA modulation in the interferon-alpha/ribavirin suppression of HIV-1 in vivo. PLoS One. 2014 Oct 2;9(10):e109220. doi: 10.1371/journal.pone.0109220. eCollection 2014.](https://ichgcp.net/es/clinical-trials-registry/publications/20381-role-of-microrna-modulation-in-the-interferon-a-ribavirin-suppression-of-hiv-1-in-vivo)\n-\n[Vandergeeten C, Fromentin R, DaFonseca S, Lawani MB, Sereti I, Lederman MM, Ramgopal M, Routy JP, Sekaly RP, Chomont N. Interleukin-7 promotes HIV persistence during antiretroviral therapy. Blood. 2013 May 23;121(21):4321-9. doi: 10.1182/blood-2012-11-465625. Epub 2013 Apr 15.](https://ichgcp.net/es/clinical-trials-registry/publications/5858-interleukin-7-promotes-hiv-persistence-during-antiretroviral-therapy)\n-\n[Cahn P, Ruxrungtham K, Gazzard B, Diaz RS, Gori A, Kotler DP, Vriesema A, Georgiou NA, Garssen J, Clerici M, Lange JM; (BTE) Blinded Nutritional Study for Immunity and Tolerance Evaluation Study Team. The immunomodulatory nutritional intervention NR100157 reduced CD4+ T-cell decline and immune activation: a 1-year multicenter randomized controlled double-blind trial in HIV-infected persons not receiving antiretroviral therapy (The BITE Study). Clin Infect Dis. 2013 Jul;57(1):139-46. doi: 10.1093/cid/cit171. Epub 2013 Mar 19.](https://ichgcp.net/es/clinical-trials-registry/publications/20382-the-immunomodulatory-nutritional-intervention-nr100157-reduced-cd4-t-cell-decline-and-immune)\n-\n[Sandler NG, Bosinger SE, Estes JD, Zhu RT, Tharp GK, Boritz E, Levin D, Wijeyesinghe S, Makamdop KN, del Prete GQ, Hill BJ, Timmer JK, Reiss E, Yarden G, Darko S, Contijoch E, Todd JP, Silvestri G, Nason M, Norgren RB Jr, Keele BF, Rao S, Langer JA, Lifson JD, Schreiber G, Douek DC. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature. 2014 Jul 31;511(7511):601-5. doi: 10.1038/nature13554. Epub 2014 Jul 9.](https://ichgcp.net/es/clinical-trials-registry/publications/20383-type-i-interferon-responses-in-rhesus-macaques-prevent-siv-infection-and-slow-disease-progression)\n-\n[Bouchat S, Gatot JS, Kabeya K, Cardona C, Colin L, Herbein G, De Wit S, Clumeck N, Lambotte O, Rouzioux C, Rohr O, Van Lint C. Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patients. AIDS. 2012 Jul 31;26(12):1473-82. doi: 10.1097/QAD.0b013e32835535f5. Erratum In: AIDS. 2013 Jun 19;27(10):1683.](https://pubmed.ncbi.nlm.nih.gov/22555163)\n-\n[Crawford TQ, Hecht FM, Pilcher CD, Ndhlovu LC, Barbour JD. Activation associated ERK1/2 signaling impairments in CD8+ T cells co-localize with blunted polyclonal and HIV-1 specific effector functions in early untreated HIV-1 infection. PLoS One. 2013 Oct 15;8(10):e77412. doi: 10.1371/journal.pone.0077412. eCollection 2013.](https://ichgcp.net/es/clinical-trials-registry/publications/20384-activation-associated-erk1-2-signaling-impairments-in-cd8-t-cells-co-localize-with-blunted)\nFechas de registro del estudio\nEstas fechas rastrean el progreso del registro del estudio y los env\u00edos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los est\u00e1ndares de control de calidad espec\u00edficos antes de publicarlos en el sitio web p\u00fablico.\nFechas importantes del estudio\nInicio del estudio (Actual)\n1 de enero de 2016\nFinalizaci\u00f3n primaria (Actual)\n1 de junio de 2017\nFinalizaci\u00f3n del estudio (Actual)\n1 de diciembre de 2017\nFechas de registro del estudio\nEnviado por primera vez\n13 de septiembre de 2015\nPrimero enviado que cumpli\u00f3 con los criterios de control de calidad\n28 de septiembre de 2015\nPublicado por primera vez (Estimar)\n30 de septiembre de 2015\nActualizaciones de registros de estudio\n\u00daltima actualizaci\u00f3n publicada (Actual)\n6 de junio de 2019\n\u00daltima actualizaci\u00f3n enviada que cumpli\u00f3 con los criterios de control de calidad\n5 de junio de 2019\n\u00daltima verificaci\u00f3n\n1 de junio de 2019\nM\u00e1s informaci\u00f3n\nT\u00e9rminos relacionados con este estudio\nPalabras clave\nOtros n\u00fameros de identificaci\u00f3n del estudio\n- 2013ZX10001004\nPlan de datos de participantes individuales (IPD)\n\u00bfPlanea compartir datos de participantes individuales (IPD)?\nIndeciso\nInformaci\u00f3n sobre medicamentos y dispositivos, documentos del estudio\nEstudia un producto farmac\u00e9utico regulado por la FDA de EE. UU.\nNo\nEstudia un producto de dispositivo regulado por la FDA de EE. UU.\nNo\nEsta informaci\u00f3n se obtuvo directamente del sitio web\n[clinicaltrials.gov](https://clinicaltrials.gov) sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comun\u00edquese con [register@clinicaltrials.gov](mailto:register@clinicaltrials.gov). Tan pronto como se implemente un cambio en [clinicaltrials.gov](https://clinicaltrials.gov), tambi\u00e9n se actualizar\u00e1 autom\u00e1ticamente en nuestro sitio web. .\nEnsayos cl\u00ednicos sobre VIH\n-\nNCT06039579A\u00fan no reclutando\n-\nNCT06037564A\u00fan no reclutandoVIH | Resistencia a las drogas | Interacci\u00f3n de drogas\n-\nNCT06033209A\u00fan no reclutando\n-\nNCT06035445A\u00fan no reclutandoVIH | Virus de inmunodeficiencia humana\n-\nNCT06034938A\u00fan no reclutando\n-\nNCT06034314A\u00fan no reclutando\n-\nNCT06032546A\u00fan no reclutando\n[Un estudio para evaluar el cambio en la actividad de la enfermedad, los eventos adversos y c\u00f3mo el f\u00e1rmaco se mueve por el cuerpo en participantes adultos que viven con el virus de la inmunodeficiencia humana (VIH) y que reciben una infusi\u00f3n intravenosa (IV) de budigalimab y/o ABBV-382](https://ichgcp.net/es/clinical-trials-registry/NCT06032546)Enfermedad por el virus de la inmunodeficiencia humana (VIH)\n-\nNCT06036238A\u00fan no reclutando\n-\nNCT06033547A\u00fan no reclutando\n-\nNCT06030557Reclutamiento\n[PrEPared-RN, CAN Manejo dirigido por enfermeras de pacientes de alto riesgo para la profilaxis previa a la exposici\u00f3n (PrEP) (Prep-RN)](https://ichgcp.net/es/clinical-trials-registry/NCT06030557)Profilaxis previa a la exposici\u00f3n (PrEP) | Prevenci\u00f3n del vih", "language": null, "image": null, "pagetype": "website", "links": ["https://ichgcp.net/es", "#", "https://ichgcp.net/de", "https://ichgcp.net/", "https://ichgcp.net/es", "https://ichgcp.net/fr", "https://ichgcp.net/it", "https://ichgcp.net/pt", "https://ichgcp.net/ru", "https://ichgcp.net/es/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects", "https://ichgcp.net/es/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol", "https://ichgcp.net/es/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia", "https://ichgcp.net/es/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan", "https://ichgcp.net/es/ich-e-group-of-guidelines", "https://ichgcp.net/es/cro-list", "https://ichgcp.net/es/clinical-trials-registry", "https://ichgcp.net/es/eu-clinical-trials-registry", "https://ichgcp.net/es/pharma-list", "https://ichgcp.net/es/labs", "https://ichgcp.net/es/service-companies", "https://ichgcp.net/es/events", "https://ichgcp.net/es/clinical-trials-registry/publications", "https://ichgcp.net/es/clinical-trials-registry/researchers", "https://ichgcp.net/es/cra-jobs", "https://ichgcp.net/es/publications", "https://ichgcp.net/es/news", "https://ichgcp.net/clinical-trials-registry/NCT02563509", "https://telegram.me/share/url?url=https://ichgcp.net/es/clinical-trials-registry/NCT02563509&text=", "https://twitter.com/intent/tweet?url=https://ichgcp.net/es/clinical-trials-registry/NCT02563509", "https://ichgcp.net/es", "https://ichgcp.net/es/clinical-trials-registry", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Guangzhou%208th%20People%27s%20Hospital", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=HIV", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=HIV-specific%20CD8%20cells", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=HIV-specific%20CD8%20cells", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Guangzhou%208th%20People%27s%20Hospital", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Sun%20Yat-sen%20University", "https://ichgcp.net/es/clinical-trials-registry/publications/20378-the-importance-of-viral-blips-and-duration-of-therapy-initiated-in-primary-infection-in-maintaining", "https://ichgcp.net/es/clinical-trials-registry/publications/20379-eradicating-hiv-1-infection-seeking-to-clear-a-persistent-pathogen", "https://ichgcp.net/es/clinical-trials-registry/publications/20380-hiv-1-tat-and-rev-upregulates-osteoclast-bone-resorption", "https://ichgcp.net/es/clinical-trials-registry/publications/20381-role-of-microrna-modulation-in-the-interferon-a-ribavirin-suppression-of-hiv-1-in-vivo", "https://ichgcp.net/es/clinical-trials-registry/publications/5858-interleukin-7-promotes-hiv-persistence-during-antiretroviral-therapy", "https://ichgcp.net/es/clinical-trials-registry/publications/20382-the-immunomodulatory-nutritional-intervention-nr100157-reduced-cd4-t-cell-decline-and-immune", "https://ichgcp.net/es/clinical-trials-registry/publications/20383-type-i-interferon-responses-in-rhesus-macaques-prevent-siv-infection-and-slow-disease-progression", "https://pubmed.ncbi.nlm.nih.gov/22555163", "https://ichgcp.net/es/clinical-trials-registry/publications/20384-activation-associated-erk1-2-signaling-impairments-in-cd8-t-cells-co-localize-with-blunted", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=HIV", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=cellular%20immunity%20therapy", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=functional%20cure", "https://clinicaltrials.gov", "mailto:register@clinicaltrials.gov", "https://clinicaltrials.gov", "https://ichgcp.net/es/clinical-trials-registry/NCT06039579", "https://ichgcp.net/es/clinical-trials-registry/NCT06037564", "https://ichgcp.net/es/clinical-trials-registry/NCT06033209", "https://ichgcp.net/es/clinical-trials-registry/NCT06035445", "https://ichgcp.net/es/clinical-trials-registry/NCT06034938", "https://ichgcp.net/es/clinical-trials-registry/NCT06034314", "https://ichgcp.net/es/clinical-trials-registry/NCT06032546", "https://ichgcp.net/es/clinical-trials-registry/NCT06036238", "https://ichgcp.net/es/clinical-trials-registry/NCT06033547", "https://ichgcp.net/es/clinical-trials-registry/NCT06030557", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=AstraZeneca", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Cairo%2BUniversity", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Assiut%2BUniversity", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=European%2BSociety%2Bof%2BHuman%2BReproduction%2Band%2BEmbryology", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Orphanetics%2BPharma%2BEntwicklungs%2BGmbH", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Universidade%2Bde%2BLisboa%252C%2BPortugal", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Kaneka%2BAmericas%2BHolding%2BInc.", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=SeeCure%2BLLC", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Pediatric%2BOrthopaedic%2BSociety%2Bof%2BNorth%2BAmerica", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Pfizer", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Mayo%2BClinic", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Jos%25C3%25A9phine%2BSOLTANI%252C%2BCardiology%2Bdepartment%252C%2BVersailles%2BHospital", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Medtronic%2BSurgical%2BTechnologies", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Novartis%2BPharmaceuticals", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=National%2BCancer%2BInstitute%2B%2528NCI%2529", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Assistance%2BPublique%2B-%2BH%25C3%25B4pitaux%2Bde%2BParis", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Universidad%2Bdel%2BZulia", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=M.D.%2BAnderson%2BCancer%2BCenter", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Center%2Bfor%2BIndustrial%2BTechnological%2BDevelopment%2Bof%2BSpain", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=GlaxoSmithKline", "https://ichgcp.net/es/clinical-trials-registry/research/browse/spns_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Asthma", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Breast%2BCancer", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Coronary%2BArtery%2BDisease", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Postneoadjuvant%2BTherapy%2BStage%2BI%2BGastric%2BCancer%2BAJCC%2Bv8", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Post-traumatic%2BAnosmia", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Pain", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Prostate%2BCancer", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Obesity", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Ultrasound%2BEvaluation", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Depression", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Ankle%2BArthroplasty", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Stage%2BI%2BGallbladder%2BCancer%2BAJCC%2Bv8", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=HIV%2BInfections", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Cushing%2527s%2BSyndrome%2BI", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Hypertension", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Stroke", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Malignant%2BNeoplasm%2Bof%2BRespiratory%2Band%2BIntrathoracic%2BOrgan%2BCarcinoma", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Colon%2BMalignant%2BTumor", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Esophageal%2BResection%2BCandidates", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Carcinoma%252C%2BAdrenal%2BCortical", "https://ichgcp.net/es/clinical-trials-registry/research/browse/cond_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Capecitabine", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cyclophosphamide", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Gemcitabine", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Valacyclovir%2Barrow", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Transplant%2B2%2BMelphalan", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Pilocarpine%2B1.25%2525%2BEye%2Bdrop", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Paclitaxel", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cisplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Prednisone", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Injectafer", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Alpelisib%2B150%2BMG%2BOral%2BTablet%2B%255BPiqray%255D", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Dexamethasone", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Teicoplanin%2BSandoz%2B200%2Bmg%2Bpowder%2Band%2Bsolvent%2Bfor%2Bsolution%2Bfor%2Binjection%2Bor%2Binfusion%2Bor%2Boral%2Bsolution.", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Brimonidine%2Btartrate%2Bophthalmic%2Bsolution%2B0.025%2525%2B%2528n%2B%253D%2B56%2529", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=20mg%2BAzilsartan%2BTablets", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Docetaxel", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Oral%2BGlucose%2BGel", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Carboplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Bevacizumab", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=MK-8521%2B100%25CE%25BCg", "https://ichgcp.net/es/clinical-trials-registry/research/browse/intr_alpha_all", "https://ichgcp.net/es/cro-list/country/bahamas", "https://ichgcp.net/es/cro-list/country/bulgaria", "https://ichgcp.net/es/cro-list/country/denmark", "https://ichgcp.net/es/cro-list/country/iran", "https://ichgcp.net/es/cro-list/country/ireland", "https://ichgcp.net/es/cro-list/country/kazakhstan", "https://ichgcp.net/es/cro-list/country/malaysia", "https://ichgcp.net/es/cro-list/country/norway", "https://ichgcp.net/es/cro-list/country/panama", "https://ichgcp.net/es/cro-list/country/poland", "https://ichgcp.net/es/cro-list/country/thailand", "https://ichgcp.net/es/cro-list/country/turkmenistan", "https://ichgcp.net/es/cro-list/country/united_kingdom", "https://ichgcp.net/es/cro-list", "https://ichgcp.net/es/cro-list/country/rwanda/company/across_global", "https://ichgcp.net/es/cro-list/country/rwanda", "https://ichgcp.net/es/clinical-trials-registry/research/browse/cond_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/cond_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/ord_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/intr_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/intr_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/diet_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/diet_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/spns_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/spns_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/locn_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/locn_cat", "https://ichgcp.net/es", "https://ichgcp.net/es/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects", "https://ichgcp.net/es/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol", "https://ichgcp.net/es/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia", "https://ichgcp.net/es/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan", "https://ichgcp.net/es/guideline-for-the-notification-of-serious-breaches-of-regulation-eu-no-536-2014", "https://ichgcp.net/es/cro-list", "https://ichgcp.net/es/pharma-list", "https://ichgcp.net/es/labs", "https://ichgcp.net/es/service-companies", "https://ichgcp.net/es/cra-jobs", "https://ichgcp.net/es/clinical-trials-registry", "https://ichgcp.net/es/eu-clinical-trials-registry", "https://ichgcp.net/es/publications", "https://ichgcp.net/es/news", "https://ichgcp.net/about-us-our-mission", "https://ichgcp.net/es/sitemap", "https://ichgcp.net/es/contact-us", "https://ichgcp.net/es/feed", "/privacy", "/disclaimer", "https://ichgcp.net/da/clinical-trials-registry/NCT02563509", "https://ichgcp.net/de/clinical-trials-registry/NCT02563509", "https://ichgcp.net/clinical-trials-registry/NCT02563509", "https://ichgcp.net/es/clinical-trials-registry/NCT02563509", "https://ichgcp.net/fr/clinical-trials-registry/NCT02563509", "https://ichgcp.net/it/clinical-trials-registry/NCT02563509", "https://ichgcp.net/hu/clinical-trials-registry/NCT02563509", "https://ichgcp.net/nl/clinical-trials-registry/NCT02563509", "https://ichgcp.net/no/clinical-trials-registry/NCT02563509", "https://ichgcp.net/pl/clinical-trials-registry/NCT02563509", "https://ichgcp.net/pt/clinical-trials-registry/NCT02563509", "https://ichgcp.net/fi/clinical-trials-registry/NCT02563509", "https://ichgcp.net/sv/clinical-trials-registry/NCT02563509", "https://ichgcp.net/cs/clinical-trials-registry/NCT02563509", "https://ichgcp.net/ru/clinical-trials-registry/NCT02563509", "https://ichgcp.net/ja/clinical-trials-registry/NCT02563509", "https://ichgcp.net/zh/clinical-trials-registry/NCT02563509", "https://ichgcp.net/ko/clinical-trials-registry/NCT02563509", "https://ichgcp.net/pdf/privacy_cookies_policy.pdf", "https://ichgcp.net/pdf/terms_of_service.pdf", "https://ichgcp.net/pdf/privacy_cookies_policy.pdf", "https://ichgcp.net/pdf/terms_of_service.pdf"]}